Search

everythinglearnresearchcommunity

for

Search:↓

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

LED light therapy at 863 nm wavelength can slow down skin tumor growth and reduce inflammation in mice.

Tridax procumbens plant parts boost immune response in mice.

Activating certain hair follicle cells could prevent hair loss from cancer treatments.

L-threonate may help prevent balding by blocking a key hair loss factor.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

More research is needed to confirm initial findings on hair loss patterns from chemotherapy.

Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Using A132 hair dye with sunlight can cause skin damage and hair loss.

The research identified unique metabolic activities in immune cells associated with hair loss in Alopecia Areata.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

Activating TLR3 helps improve skin and hair follicle regeneration after wounds.

Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.

Plucked hair can effectively monitor drug effects in cancer treatment.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

PTHrP is higher in certain dog tumors and may act as a local growth factor.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Thymic transplantation normalized some T-cells but not others, maintaining immune function.

TCDD reduces EGF receptor activity and causes various developmental changes in animals.

Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Overexpressing SSAT enzyme reduces prostate tumor growth in mice.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.